Save to wishlistSave to wishlist
有趣的是，Infigratinib最初于2021年获批用于胆管癌，后因适应症开发策略调整而主动撤回。如今，其有望在ACH赛道迎来“第二春”。基于其疗效和口服便利性，BridgeBio在今年的JPM大会上预测，该药Infigratinib将占据ACH治疗市场50%以上的份额。
。关于这个话题，一键获取谷歌浏览器下载提供了深入分析
drop-newest: Discards incoming data when full. Useful when you want to process what you have without being overwhelmed.
Speaking of brands, getting a good logo for your brand is the most frustrating